Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 54.00
Ask: 57.00
Change: 3.50 (6.73%)
Spread: 3.00 (5.556%)
Open: 52.50
High: 56.25
Low: 53.25
Prev. Close: 52.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Southern Cross, African Eagle, Avanti Communications...

Thu, 25th Nov 2010 16:17

TowerBrook Capital Partners has decided not to bid for nursing homes operator Southern Cross Healthcare. TowerBrook made what was described as "a highly preliminary proposal" in August. Southern Cross says that other parties have approached it and discussions are continuing. Full year figures will be announced on 7 December. African Eagle Resources has announced that initial drilling at its Zanzui project in Tanzania has showed the potential for a "significant" nickel oxide deposit. Additionally, the "VTEM geophysical data" from the project has identified a number of targets to enhance the prospectively of the deposit.Pharmaceutical and diagnostics technology group Avacta has announced the launch of its new AX-1 product which hopes to gain a foothold in the $1.5bn veterinary diagnostics market. The product provides an initial test to identify animals which suffer from an allergy, saving on more costly and detailed allergy tests that it could perhaps not need."There is also a much bigger opportunity for the AX-1 to address by further developing the product to deliver multiplexed testing and diagnostics for the human market", says Avacta's chief executive Alastair Smith.The human point of care testing market is valued at approximately $16bn.Satellite operator Avanti Communications first satellite HYLAS 1 is due to be launched tomorrow. The launch is due to happen between 18.39 and 21.54 GMT and can be watched on www.arianespace.com. HYLAS 2 has passed the key milestones of its critical design review and will have three times the capacity of HYLAS 1. HYLAS 2 is expected to be launched next spring. Both satellites will offer broadband services.
More News
6 Apr 2020 12:42

Avacta raises ?3.75m, expects minimal impact from pandemic

(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that, in response to "substantial" institutional interest, it has conditionally raised gross proceeds of ?3.75m under a placing, through the issue of 20,833,333 new ordinary shares at a price of 18p each.

Read more
2 Apr 2020 14:55

Avacta Announces GBP2 Million Subscription With Two Subscribers

Avacta Announces GBP2 Million Subscription With Two Subscribers

Read more
3 Feb 2020 15:22

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Read more
3 Feb 2020 10:17

Avacta signs collaboration deal with Daewoong joint venture

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced on Monday that it has signed a collaboration and license agreement with AffyXell Therapeutics - the recently-established joint venture with Daewoong Pharmaceutical - to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.

Read more
28 Jan 2020 11:57

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Read more
23 Jan 2020 12:44

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Read more
23 Jan 2020 10:28

Avacta doubles revenues thanks to LG Chem milestone payment

(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
8 Jan 2020 15:27

Avacta Group enters joint venture with South Korea's Daewoong

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.

Read more
8 Jan 2020 10:40

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Read more
13 Nov 2019 13:51

Avacta Expands Contract With LG Chem After First Programme Completes

Avacta Expands Contract With LG Chem After First Programme Completes

Read more
13 Nov 2019 11:50

Avacta Group reports solid progress in partnership with LG Chem

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.

Read more
4 Nov 2019 18:15

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Read more
18 Oct 2019 13:20

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Read more
10 Oct 2019 11:24

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.